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Abstract
The ARF tumor suppressor regulates p53 as well as basic developmental processes independent of p53, including osteoclast
activation, by controlling ribosomal biogenesis. Here we provide evidence that ARF is a master regulator of bone
remodeling and osteosarcoma (OS) development in mice. Arf-/- mice displayed increased osteoblast (OB) and osteoclast (OC)
activity with a significant net increase in trabecular bone volume. The long bones of Arf-/- mice had increased expression of
OB genes while Arf-/- OB showed enhanced differentiation in vitro. Mice transgenic for the Tax oncogene develop
lymphocytic tumors with associated osteolytic lesions, while Tax+Arf-/- mice uniformly developed spontaneous OS by 7
months of age. Tax+Arf-/- tumors were well differentiated OS characterized by an abundance of new bone with OC
recruitment, expressed OB markers and displayed intact levels of p53 mRNA and reduced Rb transcript levels. Cell lines
established from OS recapitulated characteristics of the primary tumor, including the expression of mature OB markers and
ability to form mineralized tumors when transplanted. Loss of heterozygosity in OS tumors arising in Tax+Arf+/- mice
emphasized the necessity of ARF-loss in OS development. Hypothesizing that inhibition of ARF-regulated bone remodeling
would repress development of OS, we demonstrated that treatment of Tax+Arf-/- mice with zoledronic acid, a
bisphosphonate inhibitor of OC activity and repressor of bone turnover, prevented or delayed the onset of OS. These data
describe a novel role for ARF as a regulator of bone remodeling through effects on both OB and OC. Finally, these data
underscore the potential of targeting bone remodeling as adjuvant therapy or in patients with genetic predispositions to
prevent the development of OS.
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Introduction
ARF (p14ARF in humans, p19ARF in mice) is a tumor suppressor
and a key sensor of hyperproliferative signals such as those from the
Ras and Myc oncoproteins [1]. In response to oncogenic stress,
ARF causes cell-cycle arrest in G1 and G2/M and is associated with
increased p53, p21cip and MDM2 expression [1,2]. ARF mediates
cell-cycle arrest by directly binding to MDM2 and sequesters it in
the nucleolus. Sequestration of MDM2 stabilizes and activates p53
which then blocks cellular proliferation [2,3]. Alternatively, ARF
inhibits cellular growth in a p53-independent manner by regulating
ribosomal biogenesis through nucleophosmin [3].
Arf-deficient mice develop undifferentiated sarcomas (rarely
osteosarcomas), lymphomas, and carcinomas with a mean life
expectancy of ,9 months [4]. Mice lacking both Arf and
p53 exhibit a tumor spectrum distinct from that observed in
single knockout animals, implying that ARF and p53 can act
independently to suppress tumor formation [3]. Not surprisingly,
expression of oncogenes in Arf-/- transgenic mice affects the timing
and characteristics of the tumors that arise. For example, Arf-/-
mice transgenic for Em-myc developed aggressive B cell lymphomas
with a dramatic acceleration in onset and increased mortality
when compared to Arf+/+ Em-myc mice [5]. Additionally, c-myc
overexpression in Arf-/- bone marrow resulted in the rapid
development of acute myeloid leukemia [6].
ARF possesses activities that are independent of its role as a
tumor suppressor. Arf-deficient mice succumb to blindness soon
after birth. In this case, the lack of programmed cell death within
the hyaloid vasculature leads to an accumulation of perivascular
cells and destruction of the retina and lens [7]. We have previously
described that Arf deficiency leads to increased osteoclast (OC)
function and accelerated differentiation through nucleophosmin,
independent of p53 [8]. We now report that Arf-deficient mice
also develop enhanced osteoblast (OB) function and that the
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co-regulation of OB and OC in the absence of ARF leads to
constitutively increased bone remodeling in vivo.
The role of ARF in bone remodeling carries implications for
cancer biology. p53, which is regulated by ARF, has also been
demonstrated to regulate OB function [9]. Moreover, the bone
microenvironment is known to support tumor growth in leukemia,
myeloma and solid tumor bone metastasis [10,11,12,13]. To pursue
the implications of accelerated bone remodeling on tumor
development we bred Arf-/- mice with mice expressing the viral
oncogene Tax [14]. Since the lymphoid tumors that arise in Tax
mice cause significant bone loss (osteolysis) [15,16], we hypothesized
that crossing Arf-/-mice (prone to accelerated bone remodeling) with
Tax mice (prone to osteolytic malignancies) would exacerbate
tumorigenesis and tumor mediated osteolysis. Unexpectedly, the
Tax+Arf-/- mice became highly susceptible to development of
spontaneous osteosarcoma. Osteosarcoma (OS) is the most
common primary bone malignancy, with a peak incidence in
adolescence, a time of high bone remodeling, and 5-year survival
rates in patients with metastatic or relapsed disease of ,20% [17].
p53 mutations and Rb loss is common in human OS [17] and
recent mouse models have provided clear evidence that OB-
restricted deletion of p53 and Rb leads to OS [18,19]. ARF loss is
also common in human OS [17,20]. We found that the OS that
spontaneously arose in Tax+Arf-/- mice recapitulates the malig-
nancy described in the p53/Rb OB-specific deletion models.
We further hypothesized that the increased bone remodeling in
Arf-/- mice contributed to OS development and provide evidence
that zoledronic acid, a bisphosphonate inhibitor of bone resorption,
prevented or delayed onset of OS in Tax+Arf-/- mice. These data
demonstrate that ARF regulates bone remodeling through cell
autonomous effects on both OB and OC and introduce Tax+Arf-/-
mice as a new model of spontaneous OS. This discovery implicates
bisphosphonates as novel therapeutics for targeted prevention of OS
after resection of primary OS tumors or in patients with genetic
cancer predisposition syndromes.
Methods
Animals
Arf-/- mice on a C57BL/6 background [21] were intercrossed
with transgenic mice expressing HTLV-1 Tax under the human
granzyme B promoter on a C57BL/6 x FVB background (Tax+;
previously described [14]). In all experiments, littermate Arf+/+,
Arf-/-, Tax+ and Tax+Arf-/- mice on a C57BL/6 x FVB mixed
background were used. In some experiments, Arf-/- mice were
crossed with TAX-LUC mice, a strain with granzyme B
dependent Tax expression driving firefly luciferase via the Human
T-cell lymphotropic virus type I long terminal repeat promoter,
thereby providing a bioluminescent readout of Tax-dependent
early tumor development [22]. NOD-SCID-IL2cR-/- (The
Jackson Laboratory, Bayr Harbor, Maine) mice were used for
experiments involving tumor allografts. The use of murine models
and tissues in this study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Mice
were housed under pathogen-free conditions according to the
guidelines of the Division of Comparative Medicine and all
experiments were approved by the Animal Studies Committee,
Washington University School of Medicine under protocols
20100151 (K.N.W.) and 20100026 (L.R.)
Micro–computed tomography
Femurs were suspended in agarose and femoral metaphyses
were scanned by micro–computed tomography (mCT; mCT-40;
Scanco Medical) as described previously [23,24]. For image
acquisition, the femurs were placed in a 17-mm holder and
scanned. The trabecular region was selected using contours inside
the cortical shell on each image. The growth plate was used as a
marker to determine a consistent location to start analysis and 40
slices were analyzed. A three-dimensional cubical voxel model of
bone was built, and the calculations were made as follows:
apparent bone mineral density (calibrated against a hydroxyapa-
tite phantom), relative bone volume over total bone volume
(BV/TV), trabecular number and thickness.
Bioluminescence imaging. Early tumor development and
myloperoxidase (MPO) activity were monitored by non-invasive
bioluminescence imaging of anesthetized mice (isoflurane
inhalation) following the administration of D-luciferin or luminol
as described ([22,33] respectively), in an IVIS 100 instrument
(Caliper Life Sciences, Alameda, CA).
In vivo calcein labeling and calculation of bone formation
rate
Mice were intraperitoneally injected with 20 mg/kg of calcein
(Sigma-Aldrich, St. Louis, MO) in a 2% sodium bicarbonate
solution. Mice were labeled 7 days and 2 days prior to sacrifice.
Calveria were fixed in 70% ethanol and embedded in methyl-
methacrylate and sectioned. This labeling allowed for evaluation
of bone surface (BS), single labeled surface (sLS) and double
labeled surface (dLS). These measurements were then used to
calculate bone formation rate (BFR/BS) per year as previously
described [25]. Both the concave and convex surfaces of each bone
were evaluated separately using a fluorescence microscope
(Olympus BX51, Center Valley, PA). Analysis of bone formation
rate (BFR) per bone surface (BS) was performed used Bioquant
Osteo (Bioquant Image Analysis Corp.).
Serum osteocalcin. Serum was isolated from animals and a
sandwich ELISA based assay for murine osteocalcin was
performed according to manufacturer’s instructions (Biomedical
Technologies Inc, Stoughton, MA).
RT-PCR and quantitative RT-PCR
RNA was isolated from in vitro differentiated OB or TAN OS
tumor cells using the Qiagen RNeasy mini kit (Qiagen, Valencia,
CA). To isolate RNA from whole bones or whole OS, bone
marrow was removed and bones were mechanically crushed with
a mortar and pestle and RNA extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to standard protocol. 2 mg of
RNA were subjected to DNase I digestion (Invitrogen) and RT-
PCR was carried out using SuperScript III First-Strand Synthesis
system (Invitrogen) according to manufactures instructions. 100 ng
of cDNA template were used for each reaction. Qualitative RT-
PCR was performed using RedTaq (Sigma-Aldrich, St. Louis,
MO) and quantitative RT-PCR was performed using iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA) on a CFX96 Real-Time
PCR detection system (Bio-Rad). A list of primers utilized can be
found in Table S1.
In vitro differentiation of osteoblasts. Whole bone
marrow was flushed from the femurs and tibias. The resulting
BM of one mouse was plated onto one 150 mm tissue-culture
coated dish in aMEM media (GIBCO) containing 20% FBS, L-
Glutamine, and 1% Pen-Strep (plating media). Non-adherent cells
were removed after 2 days. Adherent bone marrow stromal cells
were harvested with trypsin/EDTA at 70% confluence. For
differentiation assays, 16105 cells/well were plated into a 24 well
plate in plating media. For RNA isolation, 46105 cells/well were
plated into a 6 well plate. The following day or when cells reached
confluence, the plating media was replaced with osteogenic media
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(aMEM media, 20% FBS, L-Glutamine, 1% Pen-Strep, 50 mg/ml
ascorbic acid, and 10 mM b-glycerophosphate). Cells were
supplied fresh media every 7 days for the duration of the assay.
At indicated timepoints, cell monolayers were washed with PBS
and fixed in 10% neutral buffered formalin. Alkaline Phosphatase
staining was carried out with Fast Blue RR salt (Sigma-Aldrich).
0.4% Alizarin Red solution or Von Kossa staining (0.25 g AgNO3
in 5 ml water) was used to detect mineralized matrix.
Radiography. Development of OS was monitored by serial
x-ray imaging (Faxitron, Buffalo Grove, IL). Prior to imaging,
mice were anesthetized with a cocktail of Ketamine/Xylazine.
Histology. Bones or OS were fixed in 4% paraformaldehyde
and decalcified for 14–21 days in 14% EDTA. Paraffin-embedded
sections were stained with H&E, TRAP, or immunohistochemical
stains for Tax [22] and nucleophosmin [26] as previously
described.
Establishment of Tax+Arf-/- osteosarcoma cell line (TAN)
The TAN (Tax+ ARF null) tumor cell line was isolated from a
spontaneous mandibular OS that arose in a Tax+Arf-/- mouse. All
soft tissue was removed and the calcified tumor was mechanically
digested into small pieces using bone rongeurs and a razor blade
under sterile conditions. The small bone fragments were plated
onto tissue-culture coated dishes in 10% RPMI-1640 (Sigma)
media supplemented with 10% fetal calf serum and 1% Pen-Strep.
After 1 week, non-adherent cells and bone fragments were
removed. The adherent tumor cells were propagated.
TAN cell transplants. Mice were anesthetized and 16104
TAN cells in 50 mL PBS were injected into the left tibia. PBS was
injected into the right tibia as an internal control. Animals were
radiographed in two dimensions using an X-ray system to confirm
intratibial placement of the needle (Faxitron Corp). Alternatively,
16106 TAN cells in 100 mL PBS were injected in the tail vein and
monitored by radiography.
Zoledronic acid (ZA) dosing. ZA (Novartis Pharma AG,
Basel, Switzerland) was administered subcutaneously at a dose of
0.75 mg/mouse/week (approx. 30 mg/kg) [27] or phosphate-
buffered saline (PBS) starting at 1 month of age to Tax+Arf-/-
mice. ZA dosing was continued on a weekly basis until 9 months of
age or until the animal was moribund and sacrificed. This dosing
schedule of ZA was designed to produce drug levels similar to
those achieved with the clinical dosing regimen of 4 mg ZometaH
for the treatment of bone metastases. OS development was
monitored by manual palpation and confirmed by radiography.
Statistical Analysis. All experiments were analyzed using
Student’s t-test or one-way ANOVA in the case of experiments
with greater than three experimental groups. In calculating two-
tailed significance levels for equality of means, equal variances
were assumed for the two populations. Kaplan-Meier plots were
analyzed by the Log-rank (Mantel-Cox) Test. Results were
considered to reach significance at p,0.05 and are indicated
with an asterisk (*).
Results
Loss of the Arf tumor suppressor resulted in increased
bone formation and enhanced osteoblast differentiation
Bone remodeling is a coupled cycle of osteoblastic bone
formation and osteoclastic bone resorption [11,28,29]. We
previously demonstrated that Arf-/- mice have enhanced OC
activity through ARF effects on nucleophosmin and ribosome
biogenesis [8]. p53-/- mice have also been shown to have enhanced
OC activity; however, this is attributed to an indirect (non-cell
autonomous) increase in OB function resulting from p53 loss [9].
As the effect of ARF on OB function has not been characterized,
we performed a series of experiments to further investigate its role
in bone biology. MicroCT analysis of 8-week-old Arf-/- and Arf+/+
littermates demonstrated significant increases in bone mineral
density, trabecular bone volume and trabecular number and
thickness in Arf-/- mice (Figure 1a). This increase in bone density
was unexpected as the increased OC activity in Arf-/- mice would
typically result in decreased bone density. To further investigate
this paradox, we examined the OB compartment of Arf-/- mice.
Bone formation rates, as measured by double calcein labeling,
were significantly increased in Arf-/- mice (Figure 1b). Likewise,
increased serum levels of osteocalcin, a biomarker of mature OB,
were observed in Arf-/- mice (Figure 1c). Using quantitative real
time-PCR, we found significantly increased expression of the OB
differentiation markers osterix (OSX), alkaline phosphatase (ALP)
and osteocalcin (OCN) (Figure 1d) in long bones of Arf-/- mice
compared to littermate controls. As was observed in p53-/- OB [9]
no significant difference was seen in the expression of RUNX2 in
the absence of ARF. Although RUNX2 has been reported to
directly regulate Arf, with deficiency resulting in increased
tumorigenic potential due to loss-of-senescence [30], the increased
activity observed in Arf-/- OB was likely due to the absence of p53-
mediated repression of osterix transcription [9]. Finally, OB
differentiation was accelerated in Arf-/- mice in an in vitro
differentiation assay. Primary OB generated from Arf-/- bone
marrow stromal cells had increased ALP-positive cells and
increased matrix mineralization, a function of mature OB,
compared to cells from Arf+/+ mice (Figure 1e), consistent with
a direct cell autonomous effect of ARF loss in OB differentiation
and activity. In conjunction with the previous report of enhanced
OC activity in Arf-/- mice [8], these data demonstrate that Arf-/-
mice have both increased osteoclastic bone resorption and
osteoblastic bone formation which is consistent with increased
bone remodeling.
Loss of Arf led to development of osteosarcoma in Tax-
transgenic mice
We previously reported that mice transgenic for the HTLV-1
viral oncogene Tax spontaneously develop lymphocytic tumors
associated with hypercalcemia, osteolytic bone lesions and
enhanced OC activity [15,16]. Because osteoclastic bone resorp-
tion and high bone turnover enhance tumor growth in bone
[10,11], we hypothesized that Arf loss in Tax mice would
accelerate the growth and progression of tumors in the bone.
We did not observe an acceleration in the development of
lymphocytic tumors; however, nearly 100% of the Tax+Arf-/- mice
unexpectedly developed OS (a tumor of primary OB)
(Figures 2a,b). Calcified tumors were evident by radiography
and/or palpation in Tax+Arf-/- mice by 7 months of age, while no
OS were observed in Tax+Arf+/+ or Arf-/- animals (Figure 2c).
Notably, OS developed in Tax+Arf+/- mice with a penetrance of
approximately 50% and a median onset of 14 months of age
(Figure 2c). Tumors most frequently arose on the mandible,
possibly due to the high rate of local bone remodeling at the root
of the continuously erupting incisors [31]. Other mouse models of
spontaneous OS demonstrate a predisposition to OS development
in the mandible [18,19]. We also observed OS in the maxilla and
frontal bones of the skull in 50% of Tax+Arf-/- mice and in the
femur or tibia in approximately 10% of mice (Figure 2b, Figure
S1). Overall, the bone tumors consisted of well-demarcated,
nodular, moderately cellular, unencapsulated masses that origi-
nated in bone and expanded into and replaced existing bone. The
cells at the outer perimeter of the mass that were responsible for
the expansile growth of the tumors were OB-like with a polygonal
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morphology and amphiphilic cytoplasm. The tumors were
composed of trabecular bone interspersed with dense spindle cells
that had eosinophilic and lightly vacuolated cytoplasm, ovoid
nuclei, moderate anisocytosis/anisokaryosis and a low mitotic
index (Figure 2d). We also observed substantial numbers of OC
on the surface of the newly formed pathological bone (Figure 2e).
Serial radiological imaging (Figure 2a) and double calcein
labeling (Figure 2f) showed a rapid rate of new bone growth in
the Tax+Arf-/- tumors. These data demonstrate that Tax+Arf-/-
mice develop high penetrance spontaneous OS.
Figure 1. Loss of the Arf tumor suppressor resulted in increased bone formation and enhanced osteoblast differentiation. a) mCT
analysis of tibias from 8-week-old female Arf+/+ versus Arf-/- littermates (n = 6/genotype) mice. Bone mineral density (p = 0.0289), trabecular bone
volume (BV/TV) (p = 0.0074), trabecular number (p = 0.0117) and trabecular thickness (p = 0.0252) were significantly increased in Arf-/- tibias. b) Bone
formation was visualized by double calcein labeling 7d and 2d prior to sacrifice and visualized in the calveria. The distance between labels is directly
proportional to bone formation. Arf-/- mice showed a significant increase in bone formation rate per bone surface (p = 0.0211). c) Serum osteocalcin
levels were significantly increased in Arf-/- mice (p = 0.0376). d) Long bones of 8-week-old Arf-/- mice expressed increased transcripts of OB
differentiation markers by quantitative RT-PCR (n = 3/genotype). Data is represented as fold change following normalization to cyclophilin levels.
RUNX2= cbfa1, OSX= osterix, ALP= alkaline phosphatase, OCN=osteocalcin. Significance (*) indicates p,0.05 by Student’s T-test. e) In vitro
differentiation of OB from bone marrow stromal cells under osteogenic conditions (b-glycerophosphate and ascorbic acid). Cells were co-stained for
alkaline phosphatase (ALP) expression (purple) and mineralization (Alizarin Red) at indicated days. Note the nearly complete mineralization (red stain)
of Arf-/- wells present at each day as compared to punctate areas of mineralization present in Arf+/+ wells. Representative of .3 independent
experiments.
doi:10.1371/journal.pone.0015755.g001
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Functional Tax protein and biallelic Arf loss were
necessary for osteosarcoma development in Tax+Arf-/-
mice
The Tax oncoprotein in this model is regulated by the human
granzyme B promoter which targets expression primarily to
activated T cells and NK cells. However, Tax transcript was also
detected in non-transformed OB cultured from Tax+ mice.
Moreover, the Tax oncoprotein was detected in OS tumor cells
using immunohistochemical staining (Figure 3a). To determine if
the Tax protein expressed in the tumor retained its normal function
and specificity as a transcriptional transactivator, we generated
triple transgenic TAX-LUC-Arf-/- mice in which the HTLV-1 LTR
drives expression of firefly luciferase in tissues in which Tax is
expressed [22]. Using bioluminescent imaging to detect light
emission in live mice, we found elevated LTR activity (a reporter
for functional Tax activity) in the OS tumors (Figure 3b). Tax
expression is known to recruit inflammatory cells and OC in
lymphoid tumors [16,22,32]. Luminol-mediated bioluminescence
was used to non-invasively detect myeloperoxidase (MPO) activity
which is associated with tumor-infiltrating neutrophils and inflam-
matory cells [33]. Bioluminescence imaging using Luminol detected
elevated MPO activity in the Tax+Arf-/- OS tumors consistent with
immune cell infiltration in the OS tumors (Figure 3b).
Genetic evaluation of the Arf locus in the tumors from
Tax+Arf+/- mice demonstrated loss of heterozygosity (LOH) of
the remaining Arf allele in all OS tumors tested from Tax+Arf+/-
mice (n = 5), two by promoter methylation and three by genetic
deletion (Figure 3d). DNA extracted from tumor-free tail tissue
or from non-OS peripheral lymphocytic tumors retained the
remaining Arf allele in the heterozygous animals indicating that
LOH correlated with OS development, but did not correlate with
development of large granular lymphocytic lymphoma in the same
animal (Figure 3d). Finally, immunohistochemical staining
demonstrated that expression of nucleophosmin (NPM), an
oncogene regulated by ARF, was elevated within a sub-population
of cells present in OS tumors (Figure 3c). From these studies, we
concluded that loss of both Arf alleles was critical to OS
development. Furthermore, functional Tax protein and NPM, a
Figure 2. Loss of Arf led to development of high penetrance osteosarcoma in Tax-transgenic mice. a) Serial radiographs of a
spontaneous OS on the right jaw of a representative Tax+Arf-/- mouse from 3 months to 7 months of age. b) Radiographs of OS on the skull (right),
femur (middle) and tibia (right). c) Kaplan-Meier plot showing OS incidence in Tax+Arf-/- (red), Tax+Arf+/- (blue), Tax+Arf+/+ (black) and Arf-/- (purple)
mice. Note the decreased incidence and increased latency of OS in Tax+Arf+/- mice due to loss-of-heterozygosity. Tax+Arf-/- vs. Tax+Arf+/-, Tax+Arf+/+
and Arf-/-: p,0.001; Tax+Arf+/- vs. Tax+Arf+/+ and Arf-/-: p = 0.002 d-f) Characterization of a representative Tax+Arf-/- mandibular OS. d) H&E. Note the
trabeculae of bone formed by the OS (bright pink). e) TRAP staining demonstrating osteoclasts (red stained) lining OS bone surface. f) Double calcein
labeling, 7d and 2d prior to sacrifice, showing sites of active mineralization.
doi:10.1371/journal.pone.0015755.g002
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gene repressed by ARF, were expressed in the OS cells. Finally,
there was robust cellular recruitment to these tumors, consisting of
OC, inflammatory and immune cells.
Orthotopic inoculation of a Tax+Arf-/- osteosarcoma cell
line induced mineralized tumors
Similar to Arf-/- OB (Figure 1e), Tax+Arf-/- OB showed
increased differentiation and mineralization in vitro (Figure S2).
The presence of Tax slightly enhanced OB differentiation when
compared to wild-type cells and caused a modest increase in
Tax+Arf-/- OB differentiation relative to Arf deficiency alone. To
identify and characterize the malignant cell population within the
OS we established a cell line, herein referred to as TAN (Tax Arf
Null), from a primary mandibular OS of Tax+Arf-/- mice. TAN
cells were alkaline phosphatase positive (Figure. 4a) and when
cultured under osteogenic conditions were capable of producing
mineralized matrix as measured by von Kossa staining
(Figure 4b). In vitro, TAN cells expressed the OB differentiation
markers osterix, alkaline phosphatase, osteopontin and osteocal-
cin, as well as Tax (Figure 4c). The TAN cells had intact levels of
p53 mRNA and reduced Rb mRNA (Figure 4d) as was observed
in the primary OS tumors (Figure S3). After intratibial
inoculation, TAN cells formed radiodense tumors that could be
visualized by micro-CT (Figure 4e) and radiography (Figure 4f)
in 5 out of 10 mice at 8 weeks following transplantation.
Histological examination revealed abundant tumor cells inter-
spersed within immature osteoid (Figure 4g). Additionally,
intravenous inoculation of TAN cells resulted in multifocal lung
metastases that exhibited histology consistent with a poorly
differentiated sarcoma (Figure 4h). Collectively, these data
demonstrate that TAN tumor cells were of OB origin with the
ability to form mineralized tumors and metastasize upon
transplantation, which are key characteristics of OS. It also
suggests that RB may play a role in OS development in this model
and shows that the deletion of Arf did not affect the mRNA
expression of p53, consistent with other Arf-deficient mouse tumor
models [5,34].
Zoledronic acid administration prevented osteosarcoma
development in Tax-Arf-/- mice. OSmost commonly occurs in
adolescent children during times of bone growth and high bone
remodeling. We hypothesized that the increased bone remodeling
in the Tax+Arf-/- mice was in part responsible for OS development
in this model. Zoledronic acid (ZA), a drug commonly used for the
treatment of osteoporosis and to prevent skeletal complications of
bone metastasis, is a amino-bisphosphonate that blocks the activity
of farnesyl pyrophosphate synthase (FPPS), a key component in the
HMG-CoA reductase pathway, which is necessary for prenylation
and lipid modification of a variety of proteins including Ras, Rho
and Rac [35,36]. Bisphosphonates bind to bone with high affinity,
inhibit OC-mediated bone resorption and uncouple the cycle of
bone remodeling [37], but do not significantly alter bone formation
rates in mice [27]. We treated a cohort of Tax+Arf-/- mice with a
weekly injection of ZA from one month of age to 9 months of age.
This dosing regimen of ZA effectively reduced OC function and
resulted in the development of high bone mass osteosclerosis
(Figure 5a). In Tax mice, early and late stages of lymphoma can
be distinguished by the complete blood counts and differential
counts with elevated WBC and immature neutrophils present in the
blood in late stage disease [14]. As expected, ZA protected the
cohort from Tax-mediated hypercalcemia associated with late stage
lymphoma (Figure 5b). Strikingly, ZA treatment prevented or
delayed OS development in 8 of 9 mice (Figures 5c and 5d).
These data indicate that early administration of bisphosphonates
abrogated OS development in Tax+Arf-/- mice.
Discussion
Bone remodeling is the continuous process of resorption and new
bone formation that occurs in a healthy adult at the rate of about
10% per year [29]. The co-regulation of OC and OB is critical for
balanced remodeling and healthy bone development. This current
study implicates the ARF tumor suppressor as a critical regulator of
normal bone remodeling. In the absence of ARF, the rate of bone
remodeling is significantly accelerated and the activity of both OB
and OC is increased. The dramatic increase in bone formation is
reciprocally balanced by enhanced bone resorption, resulting in
only modest osteosclerosis in Arf-/- mice. These findings support
Figure 3. Functional Tax protein and biallelic Arf loss were
necessary for osteosarcoma development in Tax+Arf-/- mice. a)
Immunohistochemical staining of OS section for Tax (right) compared
to isotype control (left). b) In vivo bioluminescence. (Left) HTLV-1 LTR-
driven bioluminescent activity as a marker of Tax activity in OS. (Middle)
Luminol-based detection of myeloperoxidase (MPO) activity. (Right)
Radiograph. Color scale indicated is X104 photons/s/cm2/sr. c)
Immunohistochemistry for nucleophosmin (NPM) in primary Tax+Arf-/-
OS. 2 representative samples are shown. d) Genetic evaluation of the Arf
locus for loss-of-heterozygosity (LOH) in Tax+Arf+/- OS (top panel),
control Tax+Arf-/- OS, Tax+Arf-/- large granular lymphocytic (LGL)
peripheral tumor and Tax+Arf+/+ tumor-free tail tissue.
doi:10.1371/journal.pone.0015755.g003
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both p53-dependent and p53-independent actions of ARF on bone
remodeling. OC activity is increased in Arf-/- mice in part through
effects on NPM mediated ribosomal biogenesis [8] while OB
activity was enhanced in the Arf-/- mice in a p53-dependent manner
similar to that observed in the p53-/- mice [9].
The loss of ARF selectively predisposed Tax transgenic mice to
development of OS. In our study, 100% of Tax+Arf-/- mice
developed OS compared to 0% of animals with either modifica-
tion alone. Arf-deficient mice rarely develop spontaneous OS [4].
Although the absence of Arf was sufficient to promote increased
OB activation, proliferation and differentiation, other genetic hits
are likely required to promote OB transformation. p14Arf is
repressed by promoter methylation in 47% of human OS [20] and
mutated or deleted in approximately 9% of human OS [17].
Moreover, Arf mutations and modifications are associated with
decreased survival in patients with OS [20].
ARF is a well-established regulator of p53. Mice with OB
specific loss of both p53 and Rb also develop spontaneous OS.
Osterix-cre transgenic mice with p53 and Rb deletions in OB
lineage cells have revealed that loss of p53 is the rate-limiting step
Figure 4. Orthotopic inoculation of a Tax+Arf-/- osteosarcoma cell line induced mineralized tumors. a) Alkaline phosphatase (ALP,
purple) staining of Tax+Arf-null (TAN) OS line. b) von Kossa staining (black) showing mineralization of TAN cells after 10 days of culture under
osteogenic conditions. c) TAN cells express mature OB markers by RT-PCR. OSX= osterix, ALP= alkaline phosphatase, OPN=osteopontin,
OCN=osteocalcin. d) Quantitative RT-PCR for Rb (top) and p53 (bottom) expression in d20 in vitro differentiated OB from Arf+/+ (open bars), Tax+Arf-/-
(closed bars), or TAN OS cells (hatched bars). Data is represented as fold change following normalization to cyclophilin levels. Significance values of
Rb: Arf+/+ OB vs TAN p= 0.0109; Tax+Arf-/- OB vs TAN p= 0.0287. e–g) TAN cells form tumors when transplanted intratibially into
immunocompromised NSG mice. e) 3D reconstruction from microCT analysis of contralateral control tibia (top) and TAN-injected tibia (bottom).
Arrowheads note area of abnormal mineralization. f) Radiographs of tibias as in (e). g) H&E. M=marrow, T = tumor. Inset shows high power
magnification demonstrating pathological osteoid deposition (light pink). h) TAN cells metastasize to lung following intravenous transplant. H&E
staining of a metastatic lung lesion, inset shows high power magnification.
doi:10.1371/journal.pone.0015755.g004
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in initiation of OS, but that Rb loss cooperates in the steps leading
to overt malignancy [18,19]. The malignancy that arises in the
Tax+Arf-/- model is comparable to that reported in these mouse
models of OS. The loss of ARF compromises p53 function with
OB no longer able to activate p53 in response to oncogenic stimuli
[21,38]. Previous studies have not observed OS development in
Tax+p53-/- or Tax+p53+/- mice [39], however this is likely due to
the severity of generalized tumor development causing mortality
prior to the age when OS would develop.
MDM2, which is repressed by ARF, has been shown to
negatively regulate Rb [40,41]. While OS has been observed
rarely in Arf-/- mice (approximately 2%) [4], we did not observe
OS development in the Arf-/- mice on a Tax-null background
(Figure 2c). This suggests that MDM2-mediated suppression of
Rb was not likely sufficient to drive OB transformation in these
mice. Interestingly, the viral oncogeneTax has been shown to
repress Rb-like other viral oncogenes such as adenovirus E1A,
SV40 large T antigen, HPV-16 E7 and/or HCMV pp71 by
binding to RB protein and targeting it for degradation.
Although granzyme B, whose promoter drives Tax expression in
this model, was originally described to be restricted to T and NK
populations, recent data suggests that its expression may be induced
in a wider variety of normal and malignant cells, including articular
chondrocytes [42] which are derived from the same progenitor cells
as OB. Thus, expression of Tax in malignant OB could be the result
of a technical artifact such as promoter leakiness or could be
revealing previously unrealized granzyme B promoter activity
during OB differentiation. Tax is also a transcriptional activator
that regulates cytokines and growth factors and recruits inflamma-
tory cells and OC to Tax-expressing tumors [14,16]. Indeed, we
observed increased myeloperoxidase activity and prominent OC
numbers in the OS tumors. This model can be used to better
understand the role of tumor-associated stroma in OS, which could
offer new therapeutic possibilities in a tumor that has been typically
resistant to many chemotherapeutic agents.
Tax constitutively activates both the canonical and non-canonical
arms of the NFkB pathway. Inhibition of the NFkB pathway has
been shown to target OS cells lines [43] and reduce their metastatic
potential [44,45]. Interestingly, cisplatin has been recently described
as an ARFmimic in OS therapy as it represses signaling through the
NFkB pathway via the same mechanism as ARF [46]. Therefore it
is conceivable that the loss of ARF and gain of Tax in Tax+Arf-/-
mice has uncovered a role for the NFkB pathway in OS for which
new therapeutics such as proteosome inhibitors could be investi-
gated. The role of tumor associated stroma and inflammation is an
emphasis in modern cancer biology and this model will allow further
interrogation of the role these pathways in OS.
The connection between increased bone remodeling and OS has
spurred research and ongoing clinical trials examining whether
bisphosphonates are effective to treat OS. Although targeting OC
may seem counterintuitive as a therapy for OS, within the context of
living bone OC and OB regulate each other through ‘‘coupled’’
mechanisms. The therapeutic effect of zoledronic acid has been
tested in allograft models with OS cell lines, treatment of mature
tumors, and treatment of OS cells in culture (reviewed in
[47,48,49]). Furthermore, zoledronic acid decreased Ewing primary
bone tumor growth in mice [50], suggesting that such therapy may
be effective against multiple types of primary bone cancer. To date,
at least six clinical trials have been initiated to investigate the efficacy
of bisphosphonates, as a single agent or coupled with conventional
chemotherapies, in treating human OS. The therapeutic affect of
OC inhibition through RANKL targeting has also been tested in
Figure 5. Zoledronic acid administration prevented osteosarcoma development in Tax+Arf-/- mice. Tax+Arf-/- animals were treated with
0.75 ug of zoledronic acid (ZA) once weekly from 1 month until 9 months of age. Appearance of OS was monitored monthly by manual examination
and radiography. a) ZA treatment reduced OC bone resorption as shown by high trabecular bone volume. b) ZA treatment prevented hypercalcemia
in Tax+Arf-/- mice. c) Incidence of OS. p,0.0001 by Log-rank test. d) Representative radiographs of 9-month-old Tax+Arf-/- mice untreated (left) or
treated with ZA (right).
doi:10.1371/journal.pone.0015755.g005
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established preclinical models of OS and Ewing’s sarcoma [51,52].
The effect of RANKL inhibition on prevention of OS development
in the Tax+Arf-/- model is underway.
Currently, most research has focused on the treatment of
established OS. However, in a model of spontaneous OS, our data
reveal a role for bisphosphonates in the prevention or delay of OS
development. Thus, prophylactic treatment with bisphosphonates,
which have safely and effectively been used to treat Paget’s disease
of the bone [53], could benefit patients at elevated risk of developing
OS or could be used as an adjuvant therapy after removal of a
primary OS lesion. In addition to the increased risk of developing
OS secondary to radiation therapy, several genetic cancer
syndromes exist that place affected people at high risk for OS
development. Alterations and mutations in the p53, retinoblastoma
(RB) or neurofibromatosis1 (NF1) pathways predispose patients to
OS [54,55,56] and components are these pathways are commonly
mutated in spontaneous human OS [17]. Notably, the incidence of
OS is markedly increased in patients with hereditary retinoblastoma
[57] and in patients with the autosomal dominant Li Fraumini p53
mutations [54]. The diminished cost of genomic sequencing has
enabled more testing for cancer predisposition syndromes. For
example NF1mutations occur in 1 in 1000 people and NF1 patients
are at increased risk for OS [58]. Our data would suggest that
clinical trials to evaluate agents like zoledronic acid in the
prevention of OS in high-risk populations and to prevent recurrence
and metastasis after resection/treatment of primary OS tumors
should be considered [57]. Preclinical studies demonstrate that ZA
can decrease prostate cancer osteoblastic bone metastasis and tumor
growth [59]. Bisphosphonate administration to patients with
localized breast cancer has been associated with improved
disease-free survival, decreased metastasis, lower occurrence of
new breast cancers and decreased numbers of bone marrow
micrometastases [60,61]. Here we report a role for bisphosphonates
in the prevention of OS development in a high risk model, which
would be difficult to evaluate using xenograft models of established
OS and osteoblastic metastases.
In summary, our data suggest a role for ARF as a regulator of
normal bone remodeling and malignant bone tumor formation.
The sensitivity of OS development to repression of bone
resorption broadens the range of potential therapeutic prevention
targets for patients at high risk for OS development.
Supporting Information
Table S1 Primers utilized for qualitative and quantita-
tive PCR.
(DOC)
Figure S1 Tax+Arf-/- osteosarcoma tumors arise pri-
marily in jaw and skull bones. The locations of n= 50 OS
tumors arising in Tax+Arf-/- mice. The majority of tumors arose in
the mandible, often presenting with malocclusion prior to palpable
tumor. Other bones of the skull include the frontal, parietal and
premaxillary lobes. Maxillary bones contain the upper incisors and
upper molars. Tumors occasionally arise in the long bones of the
legs, however, these arise much later than the tumors of the skull
and jaw.
(TIF)
Figure S2 The expression of Tax did not cause a further
significant increase in Tax+Arf-/- osteoblast differentia-
tion relative to Arf deficiency alone. In vitro differentiation of
Arf+/+, Tax+, Arf-/- and Tax+Arf-/- OB from primary bone marrow
stromal cells under osteogenic conditions (b-glycerophosphate and
ascorbic acid). Cells were co-stained for alkaline phosphatase
expression (purple) and mineralization (Alizarin Red) at indicated
days. Representative of.3 independent experiments. Note that the
experiment presented here is the same presented in Fig 1e.
(TIF)
Figure S3 Tax+Arf-/- primary osteosarcoma have re-
duced levels of Rb transcript but intact levels of p53
transcript. Quantitative RT-PCR for Rb (A) and p53 (B)
expression in Arf+/+ tumor-free bone (open bars), Tax+Arf-/-
tumor-free bone (closed bars) or Tax+Arf-/- primary mandibular
OS (hatched bars). N= 3/group. Data is represented as fold
change following normalization to cyclophilin levels. Significance
values of Rb: Arf+/+ normal bone vs Tax+Arf-/- OS p=0.0027;
Tax+Arf-/- normal bone vs Tax+Arf-/- OS p=0.0004.
(TIF)
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